Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Elena Ardini, Salvatore Siena

Journal title: ESMO Open

Journal number: 5/5

Journal publisher: Cancer Epidemiology

Published year: 2020

Published pages: e000867

DOI identifier: 10.1136/esmoopen-2020-000867

ISSN: 2059-7029